ORIGINAL INVESTIGATION. Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy
|
|
- Blake Mason
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy Carolyn J. Crandall, MD, MS; Arun Karlamangla, MD, PhD; Mei-Hua Huang, DrPH; Giske Ursin, PhD; Min Guan, MS; Gail A. Greendale, MD Background: Postmenopausal use of estrogen and progestin therapy increases breast density and breast discomfort. Whether this increase in breast density is heralded by new-onset breast discomfort is unknown. Methods: We used data from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study, which retrieved and examined baseline and 12- month mammograms for 594 (67.9%) of 875 women aged 45 to 64 years enrolled in the randomized controlled trial. Treatments included placebo, mg/d of conjugated equine estrogens, mg/d of conjugated equine estrogens and medroxyprogesterone acetate (10 mg/d for 12 d/mo or 2.5 mg/d continuously), or mg/d of conjugated equine estrogens and 200 mg/d of micronized progestin for 12 d/mo. Breast density (the percent of the breast composed of dense tissue) was calculated from digitized mammograms obtained at baseline and at 12- month follow-up. Breast discomfort was ascertained at baseline and at follow-up using standardized self-report questionnaires. In bivariate analysis, and then in multivariable linear regression models, we assessed the association between change in percent breast density from baseline to 12-month follow-up and new-onset breast discomfort in participants who had no breast discomfort at baseline (N=533). Results: After adjustment for age, treatment assignment (placebo, conjugated equine estrogens, or progestincontaining regimen), and other potential confounders, women with new-onset breast discomfort had a 3.9% increase in percent breast density compared with a 0.6% increase in percent breast density among women without new-onset breast discomfort ( =.033, P.001). The association between incident breast discomfort and increased percent breast density was similar in all active treatment arms. Conclusion: In postmenopausal women randomly assigned to menopausal hormone therapy vs placebo, newonset breast discomfort is associated with increased mammographic density. Arch Intern Med. 2006;166: Author Affiliations: Divisions of General Internal Medicine (Dr Crandall) and Geriatrics (Drs Karlamangla, Huang, and Greendale), The David Geffen School of Medicine at UCLA, and Department of Biostatistics (Ms Guan), University of California, Los Angeles; Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles; and Department of Nutrition, University of Oslo, Oslo, Norway (Dr Ursin). HIGH ENDOGENOUSLY OCcurring mammographic density (ie, that which occurs in the absence of pharmacological stimulus) is a well-established, strong, independent risk factor for breast cancer. 1-3 Women with dense tissue in more than 75% of the breast have a 4-fold higher risk of developing breast cancer compared with women with little or no density in the breast. 2,4 In ranking the importance of known risk factors for breast cancer, the American Cancer Society 3 includes high breast density in the highest risk category. Increase in breast density is a known effect of combined (estrogen and progestin) hormone therapy (HT). 5,6 Whether the gain in breast density that results from combination HT signals an increase in breast cancer risk remains unknown. Breast discomfort is another effect of menopausal HT. Whereas the natural history of breast discomfort is to decrease with the menopausal transition, 7,8 results of the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial 9 and other randomized controlled trials 10,11 demonstrate that breast discomfort increases with administration of combined estrogen and progestin therapy. Results of prior studies 12,13 suggest that new-onset breast discomfort during menopausal HT increased breast density, but causal inference is inconclusive because of study limitations. In both of these studies, HT assignment was nonrandomized, and participants were unblinded to treatment. We examined the association between new-onset breast discomfort during 12 months of HT administration and increase in percent breast density during the same period. We used data from the PEPI Mammographic Density Study (PEPI- MDS), a longitudinal study of the deter- 1578
2 minants of mammographic density and change in mammographic density in women receiving vs those not receiving menopausal HT. 5,14-16 METHODS PARTICIPANTS Data for this analysis came from the PEPI-MDS, an independent study initiated after the PEPI trial was completed. The PEPI trial design has been described in detail. 17 In brief, the PEPI trial was a double-blind, randomized, controlled trial designed to compare the effects of placebo and several regimens of orally administered menopausal HT on cardiovascular disease risk factors in postmenopausal women recruited between December 27, 1989, and February 8, 1991, by the following 7 participating centers: George Washington University, Washington, DC; The Johns Hopkins University, Baltimore, Md; Stanford University, Stanford, Calif; University of California, Los Angeles; University of California, San Diego; University of Iowa, Iowa City; and University of Texas Health Science Center, San Antonio. The treatment regimens were placebo (placebo arm), mg/d of conjugated equine estrogens (CEE arm), mg/d of conjugated equine estrogens and 10 mg/d of medroxyprogesterone acetate for 12 d/mo (CEE and cyclical MPA arm), mg/d of conjugated equine estrogens and 2.5 mg/d of medroxyprogesterone acetate continuously (CEE and continuous MPA arm), or mg/d of conjugated equine estrogens and 200 mg/d of micronized progestin for 12 d/mo (CEE and MP arm). The 875 PEPI trial participants (of 1557 women screened) had to be between 45 and 64 years old and had been menopausal for at least 1 year at enrollment into the trial. Women with any major contraindication to the use of combined estrogen or progestin therapy (eg, breast cancer) were excluded. 17 The PEPI-MDS was designed to elucidate hormonal, genetic, and lifestyle determinants of breast density. Of 875 PEPI trial participants, 603 had retrievable baseline mammograms. Of these, 7 women had breast implants and 2 women s mammograms were technically inadequate. As a result of these exclusions, mammograms from 594 women (67.9% of 875 women in the PEPI trial) were examined in the PEPI-MDS. 5,14-16 Fifty-two of 594 women in the PEPI-MDS had reported breast discomfort at baseline and were excluded from the present study. An additional 9 women were excluded because breast discomfort information was unavailable for them at 12-month followup, leaving us with an analytic sample size of 533. MEASUREMENTS Information about age, ethnicity, cigarette smoking, alcohol use, physical activity level, parity, ethnicity, prior hysterectomy, years since menopause, and presence of breast discomfort came from standardized self-report questionnaires. 17 The following specific questions regarding breast discomfort were asked at baseline and at 12-month follow-up: During the past week including today, did any of these symptoms bother you or interfere with your life? Breast sensitivity/tenderness (yes or no), painful breasts (yes or no). We classified women who reported breast sensitivity/tenderness (yes or no) and/or painful breasts (yes or no) as having breast discomfort. Weight and height were measured at baseline. 17 Compliance with treatment was defined as having taken at least 80% of study medication at 6-month and 12-month follow-up visits, verified by pill count. The serum estrone level was measured from fasting blood samples drawn at baseline and at 12-month follow-up and was analyzed using radioimmunoassay as previously described. 15 Interassay and intra-assay coefficients of variation for serum estrone were 15% and 16%, respectively. The lower limit of detection of the estrone assay was 3 pg/ml. Prerandomization conventional craniocaudal mammograms obtained between 1989 and 1994 during the original PEPI study were retrieved from the 7 participating PEPI trial clinical centers. Percent breast density was quantified by a single reader (G.U.) as the percent of the breast image that was composed of dense tissue using methods detailed previously. 5,18 In brief, mammograms were digitized at a resolution of 150 pixels per square inch. Breast tissue was outlined on the digitized mammogram image by the reader; next, the reader established for each image a density threshold above which breast tissue was to be considered dense and a density threshold below which breast tissue was to be considered nondense. The software calculated percent breast density as the ratio of the total area of dense breast tissue in the image to the total area of the breast tissue. Reasons for exclusion included the presence of breast implants or technical inadequacy such as excessively dark images that precluded the reader s ability to define the breast and to set a density threshold. The intrarater reliability for percent breast density was high: intraclass correlation coefficients were greater than 0.95 for mammograms that were rated as not difficult to read or as slightly difficult to read, and greater than 0.91 for mammograms that were difficult to read or very difficult to read (as judged by the reader). 5 Previous findings have documented the high interrater reliability of this technique for breast density assessment. 19 STATISTICAL ANALYSIS We compared key demographic and lifestyle-related characteristics of the analytic sample with those of the remainder of the PEPI trial participants using t test (continuous variables) or 2 test (categorical variables). Because baseline percent breast density was not normally distributed, we compared baseline percent breast density in women who had baseline breast discomfort vs those who did not have baseline breast discomfort using Wilcoxon rank sum test. In the longitudinal sample of 533 women without baseline breast discomfort, we compared the mean 12-month change in percent breast density in women who had new-onset breast discomfort vs those who did not have new-onset breast discomfort using t test. We then adjusted for potential confounders using a multivariable linear regression model with change in percent breast density as the outcome and incident breast discomfort (yes or no) as the main predictor. The incidence of new-onset breast discomfort and the 12-month change in percent breast density were similar among women assigned to the 3 progestin-containing regimens. Therefore, we grouped the progestin arms and included treatment arm as a 3-level covariate composed of placebo, CEE alone, and any progestincontaining regimens. We also included pill compliance as a covariate. Other covariates for the regression models, chosen on the basis of prior publications, biological plausibility, and statistical considerations, included current smoking (yes or no), 20 ethnicity (white vs nonwhite), age (continuous), 2,26 number of pregnancies resulting in live births (continuous), age at first pregnancy (continuous), 20-22,27,28 body mass index (continuous), 20,22,23,27-30 alcohol consumption (continuous), 28 and log-transformed baseline percent breast density. We considered potential interactions by adding interaction terms to the linear regression models containing these covariates. To assess the statistical significance of each interaction term, we evaluated the P values for the interaction term in the linear regression model. Interaction terms were dropped from the model if P.10 for tests of significance. Four poten- 1579
3 Table 1. Baseline Characteristics of the Analytic Sample Compared With Those of the Excluded PEPI-MDS Participants a Characteristic Remainder of PEPI-MDS Participants (n = 61) b Excluded Because of Baseline Breast Discomfort (n = 61) Excluded PEPI-MDS Participants b Remainder of Excluded Participants (n = 281) Age, y 56.1 ± ± ± 4.3 Years since menopause c 5.6 ± ± ± 2.8 Body mass index d 26.0 ± ± ± 4.3 Prior use of hormone therapy e 295 (55.3) 34 (55.7) 163 (58.0) Recency of hormone therapy use, mo f 25.4 ± ± ± 55.0 Smoking Current 69 (12.9) 8 (13.1) 41 (14.6) Former 202 (37.9) 23 (37.7) 100 (35.6) Never 262 (49.2) 30 (49.2) 140 (49.8) Alcohol use, g/d 6.5 ± ± ± 11.5 Level of physical activity g Low 362 (67.9) 38 (62.3) 175 (62.3) Medium 166 (31.1) 23 (37.7) 105 (37.4) High 5 (0.9) 0 1 (0.4) Nonwhite ethnicity 62 (11.6) 10 (16.4) 28 (10.0) Compliance with treatment assignment h 467 (87.6) 52 (85.2) 230 (81.9) Uncertain menopause i 123 (23.1) 19 (31.1) 78 (27.8) Hysterectomy j 154 (28.9) 25 (41.0) 100 (35.6) Baseline % breast density, median (IQR) k 23.8 (28.0) 19.0 (30.4) Not applicable Abbreviations: IQR, interquartile range; PEPI-MDS, Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. a Most (52 of 61 participants) had baseline breast discomfort. b Data are given as mean ± SD or as number (percent) unless otherwise indicated. c The last menstrual period for women who had a hysterectomy with bilateral oophorectomy was considered to be the date of the hysterectomy. Because of some missing answers, sample sizes for years since menopause were 36 (women with baseline breast discomfort), 417 (women without baseline breast discomfort), and 204 (remainder of PEPI-MDS participants). d Calculated as weight in kilograms divided by the square of height in meters. e Women were allowed to enroll in the PEPI-MDS trial if they discontinued menopausal hormone therapy for at least 2 months before the first screening visit. f Months elapsed since menopausal hormone therapy use (based on baseline visit and self-reported date of last use) in those participants who reported prior use of hormone therapy. Because of some missing answers, sample sizes for recency of hormone therapy use were 29 (women with baseline breast discomfort), 295 (women without baseline breast discomfort), and 153 (remainder of PEPI-MDS participants). g Self-scored as 1 (inactive), 2 (light), 3 (moderate), or 4 (heavy) for each domain of exercise (leisure and home) and categorized as low ( 1.5), medium ( 1.5 and 3), or high ( 3). Calculated as one half of leisure plus home scores minus 1. h Compliant with at least 80% of study medication at both 6 months and 12 months. i Menopause status was deemed uncertain if a woman reported having had a hysterectomy with at least 1 intact ovary or a hysterectomy with an uncertain number of intact ovaries. j Surgical removal of the uterus, with or without oophorectomy. k Percentage of the breast that is dense, as determined using the semiautomated interactive threshold method by Ursin et al. 18 Because baseline percent breast density was not normally distributed, values are given as median (IQR). tial interactions were tested. First, to assess whether the relation between incident breast discomfort and increase in percent breast density was different according to treatment arm, we included a treatment assignment new-onset breast discomfort interaction term. Second, to address the possibility that the association between new-onset breast discomfort and change in mammographic density could be stronger in women who were compliant with treatment assignment, we tested for compliance- new-onset breast discomfort interaction. Third, we tested for compliance- treatment assignment interaction. Fourth, to determine whether the association between newonset breast discomfort and change in percent breast density is modified by recent HT use (ie, quitting hormones to join the PEPI trial), we added an interaction term (recent hormone use new-onset breast discomfort) to the linear regression model containing the covariates. The PEPI-MDS previously reported that change in percent breast density was related to the magnitude of change in estrone level during menopausal combined estrogen and progestin therapy. 15 Therefore, in secondary analyses, we added baseline estrone level and change in estrone level to the model to assess whether the new-onset breast discomfort change in percent breast density link was mediated by change in estrone level. All statistical tests were 2-sided. P.05 for main terms (or P.10 for interaction terms) was considered statistically significant. Statistical analyses were performed using SAS version 9.0 (SAS Institute Inc, Cary, NC). The protocol was approved by the institutional review boards at each participating center. RESULTS DESCRIPTIVE STATISTICS The 533 participants included in the present analysis were similar to the rest of the PEPI trial participants for variables of interest (Table 1). Participants in the analytic sample were on average 56.1 years old and had been menopausal for 5.6 years. Most were white and nonsmokers. These women were also similar to the 61 PEPI-MDS participants who were excluded on the basis of baseline breast discomfort (n=52) or lack of follow-up discomfort information (n=9). A higher proportion of the 61 excluded 1580
4 % 27.5% % of Women With New-Onset Discomfort % 12.5% 14.8% 23.2% Entire Group (N = 533) Placebo (n = 104) CEE (n = 108) (P =.62) Treatment Arm CEE + Cyclical MPA (n = 100) (P <.01) CEE + Continuous MPA (n = 112) (P =.04) CEE + Micronized Progestin (n = 109) (P <.01) Figure 1. Percentage of women with new-onset breast discomfort in the full sample and by treatment arm. Women were considered to have new-onset breast discomfort if they acknowledged having breast sensitivity/tenderness, breast pain, or both. Values are unadjusted for other covariates. Error bars represent 95% confidence limits. P values refer to comparison with the placebo arm. CEE indicates conjugated equine estrogens; MPA, medroxyprogesterone acetate. women had prior hysterectomy compared with participants included in our analytic sample. The median baseline percent breast density did not differ between the 2 groups (19.0% in the excluded group vs 23.8% in the analytic sample; P=.13, Wilcoxon rank sum test). The overall group median percent breast density at baseline was 23.6% (interquartile range, 28.1%). The baseline percent breast density was similar by treatment arm (P=.97, analysis of variance test of difference by treatment arm). The prevalence of breast discomfort at baseline was also similar among treatment arms (range, 7.6%- 9.7%; P=.98, 2 test of difference by treatment arms). In the 533 women in our analytic sample, the incidence of new-onset breast discomfort at 12-month follow-up was 21.2%. The incidence differed statistically among treatment arms: 12.5%, 14.8%, 28.0%, 23.2%, and 27.5%, respectively, in the placebo arm, CEE arm, CEE and cyclical MPA arm, CEE and continuous MPA arm, and CEE and MP arm (P=.01, overall 2 test) (Figure 1). Compared with the placebo and CEE-only arms, in which the risks of new-onset breast discomfort were 12.5% and 14.8%, respectively, the risks in the 3 progestincontaining arms were about double (range, 23.2%- 28.0%) (Figure 1) (range, P=.04 to P=.006 for comparison of the 3 progestin-containing arms with the placebo arm and P=.02 to P=.11 for comparison of the 3 progestincontaining arms with the CEE alone arm). The occurrence of new-onset breast discomfort did not differ significantly among the 3 progestin-containing arms (range, P=.42 to P=.96 for pairwise comparisons). The occurrence of new-onset breast discomfort was 26.2% in the aggregated progestin-containing arms, significantly higher than that in the CEE-only arm (P=.02) and in the placebo arm (P.01), as demonstrated in a prior PEPI study. 9 The incidence of new-onset breast discomfort in the CEEonly arm was not statistically different from that in the placebo arm (P=.62). The mean±sd 12-month increase in percent breast density (12-month percent breast density minus baseline percent breast density) was 2.7% ±8.7%. Figure 2 shows that at 12 months the percent breast density had decreased 0.4% in the placebo arm and had increased in the CEE arm (0.9%), CEE and cyclical MPA arm (4.6%), CEE and continuous MPA arm (4.4%), and CEE and MP arm (3.1%). The mean change in percent breast density was not different among the 3 progestin-containing arms (P=.68). Taken as a single group, the change in percent breast density was 4.0% in the progestin-containing arms, and this was significantly higher than that in the CEEonly arm (P=.001) and in the placebo arm (P.001). The change in percent breast density in the CEE-only arm was not significantly higher than that in the placebo arm (P=.25). UNADJUSTED AND ADJUSTED PRIMARY ASSOCIATION The mean change in percent breast density was higher in women who had new-onset breast discomfort vs those who did not have new-onset breast discomfort (5.4% vs 1.8%, P.001). After adjustment for parity, age at baseline, age at first pregnancy, body mass index, alcohol intake, smoking, ethnicity, baseline percent breast density, compliance with treatment in a linear regression model, and treatment arm assignment (placebo, CEEonly, or progestin-containing regimen), women with newonset breast discomfort had a 3.5% increase in percent breast density compared with a 0.2% increase in women without new-onset breast discomfort ( =.033, P.001). 1581
5 % 4.4% % Change in % Breast Density % 0.9% % Entire Group (N = 522) Placebo (n = 103) CEE (n = 105) (P =.25) Treatment Arm CEE + Cyclical MPA (n = 99) (P =.003) CEE + Continuous MPA (n = 112) (P <.001) CEE + Micronized Progestin (n = 105) (P <.001) Figure 2. Twelve-month unadjusted change in percent breast density in the full sample and by treatment arm. The percent breast density was determined from digitized mammograms using an interactive threshold method by Ursin et al. 18 Error bars represent 95% confidence limits. P values refer to comparison with the placebo arm. CEE indicates conjugated equine estrogens; MPA, medroxyprogesterone acetate. Table 2. Association Between New-Onset Breast Discomfort and Change in Percentage Breast Density* Predictor Effect of Predictor on Change in % Breast Density SE of Change P Value New-onset breast discomfort Log-transformed baseline percent breast density Age Parity Body mass index Alcohol use Smoking White ethnicity Compliance with treatment assignment Progestin-containing therapy vs placebo Conjugated equine estrogens only therapy vs placebo *Percentage of the breast that is dense, as determined using the semiautomated interactive threshold method by Ursin et al. 18 The mean change in percent breast density was 3.9% for women with new-onset breast discomfort and 0.6% for women without new-onset breast discomfort. TESTS OF EFFECT MODIFICATION We next added a treatment assignment -compliance interaction term to the linear regression model. After inclusion of the treatment assignment -compliance interaction term in the model, women with new-onset breast discomfort had a 3.9% increase in percent breast density compared with a 0.6% increase in percent breast density among women without new-onset breast discomfort ( =.033, P.001) (Table 2). The compliance- new-onset breast discomfort interaction was statistically nonsignificant (P=.32), indicating that compliance with treatment did not affect the association between new-onset breast discomfort and change in percent breast density. Therefore, this interaction term was omitted from the final model. Recent use of HT before joining the PEPI trial also did not affect the association between new-onset breast discomfort and change in percent breast density (P=.42 for the interaction term, =.033 without the interaction term and =.036 with the interaction term). The treatment assignment new-onset breast discomfort interaction term was of borderline statistical significance (P=.15) with reference to our predesignated interaction term cutoff (P.1). The inability to detect effect modification by treatment arm assignment might reflect the small treatment arm sizes and not a true uniformity of the association between new-onset breast discomfort and increase in percent breast density across treatment arms. Figure 3 shows the mean change in percent breast density in women who had new-onset breast discomfort vs those who did not have new-onset breast discomfort before and after stratification by treatment arm. Although the effect of new-onset breast discomfort on increase in percent breast density seemed to be markedly greater in women assigned to progestin-containing therapies, this trend was statistically nonsignificant (P=.15, test of effect modification by treatment arm). 1582
6 SECONDARY EXPLORATORY ANALYSIS In secondary analyses designed to explore whether the relation between incident breast discomfort and change in percent breast density was mediated by the increase in estrone level during postmenopausal HT, we added baseline estrone level and change in estrone level to the final linear regression model. Although change in estrone level significantly predicted change in percent breast density (P=.01), new-onset breast discomfort remained a significant predictor of change in percent breast density ( =.030, P.01). Change in % Breast Density % Without Discomfort With Discomfort 3.9% 0.5% 0.3% 1.7% 1.1% 4.0% 8.4% COMMENT The primary research question of this study was Does new-onset breast discomfort herald increased percent breast density? Our findings suggest that the answer is yes. The results of 2 previous studies 12,13 suggest a link between HT-induced breast discomfort and increased breast density; however, these studies were nonrandomized and unblinded. The lack of blinding is a particularly important limitation because breast discomfort data are self-reported. If increased mammographic density during HT is indicative of increased breast cancer risk, new-onset breast discomfort during HT may be a marker of increased risk of breast cancer. While the PEPI-MDS showed that estrogen and progestin therapy increases mammographic density, 5 the present analysis shows that new-onset breast discomfort provides additional independent information that distinguishes women who experience greater increases in percent breast density during HT. Neither the magnitude of the association between incident breast discomfort and increase in percent breast density, nor the statistical significance of this association, was altered by adjustment for baseline estrone level and change in estrone level. This observation underscores the importance of considering the possible roles of growth factors, sex hormone binding globulin, and other estrogens, estrone metabolites, or sex steroids as mediators of this association between new-onset breast discomfort and change in breast density. 31 The limitations of our study are that it could not capture any breast discomfort that appeared and resolved between the baseline and 12-month assessments and that we did not assess changes in the severity of breast discomfort. Our study also did not allow us to evaluate the chronological sequence (ie, we cannot determine whether the mammographic density change preceded or followed the onset of breast discomfort). The association between new-onset breast discomfort and increase in percent breast density may not be the same for other estrogens and progestins compared with those used in the PEPI trial. Finally, the link between increased breast density in the context of HT use and possible increased risk of breast cancer remains unproven. The strengths of the PEPI-MDS include the high level of participant compliance with assigned therapy, a detailed standardized questionnaire that supplied information about multiple characteristics linked with mammographic density, the best available means of assessing 1.0 Entire Group Placebo (Reference) 0.5% Treatment Assignment mammographic density, and a prospective, placebocontrolled, randomized, blinded design. CONCLUSIONS CEE CEE + Progestin Figure 3. Adjusted mean change in percent breast density by new-onset breast discomfort, before and after stratification by treatment assignment. Change in percent breast density represents the mean change in percent breast density from baseline to 12-month follow-up, adjusted for covariates. The results stratified by treatment assignment are for women who were compliant with therapy. CEE indicates conjugated equine estrogens. In postmenopausal women without breast discomfort before the initiation of CEE or CEE and a progestin, newonset breast discomfort signals increased mammographic density independent of the actual therapy regimen. If increased mammographic density is indicative of increased breast cancer risk during HT, our findings suggest that new-onset breast discomfort during therapy might be a useful clinical marker for increased risk of breast cancer. We expect to test this hypothesis in future studies with breast cancer outcomes. The mechanisms behind HT-associated increases in breast discomfort and mammographic density, and the potential utility of surveillance strategies for women who develop newonset breast discomfort during menopausal HT, deserve further investigation. Accepted for Publication: May 11, Correspondence: Carolyn J. Crandall, MD, MS, Division of Internal Medicine, The David Geffen School of Medicine at UCLA, University of California, Los Angeles, 911 Broxton Ave, First Floor, Los Angeles, CA (ccrandall@mednet.ucla.edu). Author Contributions: Dr Crandall had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial Disclosure: None reported. Funding/Support: This study was supported by grant 8KB-0035 from the California Breast Cancer Research Program, by grant 5K12AG01004 from the National Institute on Aging, and by grant 2R01 CA (to Dr Greendale) from the National Institutes of Health. Role of the Sponsors: The funding sources did not participate in the design or conduct of the study; collec- 1583
7 tion, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. Acknowledgment: We thank the women who generously participated in the PEPI trial. REFERENCES 1. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7: Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology. 2004;230: American Cancer Society. Breast Cancer Facts and Figures Atlanta, Ga: American Cancer Society; Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6: Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95: McTiernan A, Martin CF, Peck JD, et al; Women s Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women s Health Initiative randomized trial. J Natl Cancer Inst. 2005;97: Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective populationbased study of menopausal symptoms. Obstet Gynecol. 2000;96: Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. BMJ. 1980;281: Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/ Progestin Interventions trial. Obstet Gynecol. 1998;92: Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatmentrelated effects of estrogen and progestin in the Women s Health Initiative. Obstet Gynecol. 2005;105: Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75: Bulbul NH, Ozden S, Dayicioglu V. Effects of hormone replacement therapy on mammographic findings. Arch Gynecol Obstet. 2003;268: McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol. 1994; 163: Greendale GA, Reboussin BA, Sie A, et al; Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 1999;130: Ursin G, Palla SL, Reboussin BA, et al. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Clin Oncol. 2004;22: Greendale GA, Palla SL, Ursin G, et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol. 2005;162: Espeland MA, Bush TL, Mebane-Sims I, et al. Rationale, design, and conduct of the PEPI trial: Postmenopausal Estrogen/Progestin Interventions. Control Clin Trials. 1995;16(suppl):3S-19S. 18. Ursin G, Astrahan MA, Salane M, et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev. 1998;7: Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994;39: Jeffreys M, Warren R, Gunnell D, McCarron P, Smith GD. Life course breast cancer risk factors and adult breast density (United Kingdom). Cancer Causes Control. 2004;15: El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes Control. 2000;11: Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst. 2005;97: Martin C, Peck J, Pisano E, Davis C, McTiernan A, Hulka B. Prior HRT use, ethnicity and mammographic density. Ann Epidemiol. 2000;10: Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer. 2003;107: del Carmen MG, Hughes KS, Halpern E, et al. Racial differences in mammographic breast density. Cancer. 2003;98: Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003;12: Heng D, Gao F, Jong R, et al. Risk factors for breast cancer associated with mammographic features in Singaporean Chinese women. Cancer Epidemiol Biomarkers Prev. 2004;13: Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000;11: Gapstur SM, Lopez P, Colangelo LA, Wolfman J, Van Horn L, Hendrick RE. Associations of breast cancer risk factors with breast density in Hispanic women. Cancer Epidemiol Biomarkers Prev. 2003;12: McCormack VA, dos Santos Silva I, De Stavola BL, et al. Life-course body size and perimenopausal mammographic parenchymal patterns in the MRC 1946 British birth cohort. Br J Cancer. 2003;89: Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004;81:
8 4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202: Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335: MacMahon SW, Cutler JA, Furberg CD, Payne GH. Theeffects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized clinical trials. Prog Cardiovasc Dis. 1986;29(3) (suppl 1): SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265: Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248: Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270: Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91: MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304: Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290: Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43: British Hypertension Society. NICE/BHS Clinical guideline 34: Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. Accessed August 17, Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005; 95: Correction Incorrect Total Sample Size Reported in Table 1. In the Original Investigation titled Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy, by Crandall et al, published in the August 14/28 issue of the ARCHIVES (2006;166: ), the total sample size was incorrectly reported in Table 1 on page In the column labeled Remainder of PEPI-MDS Participants, the value should have been (N=533). (REPRINTED) ARCH INTERN MED/ VOL 166, NOV 13,
ARTICLES. Postmenopausal Hormone Therapy and Change in Mammographic Density
ARTICLES Postmenopausal Hormone Therapy and Change in Mammographic Density Gail A. Greendale, Beth A. Reboussin, Stacey Slone, Carol Wasilauskas, Malcolm C. Pike, Giske Ursin Background: Mammographic density
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationHormone replacement therapy and breast density after surgical menopause
Hormone replacement therapy and breast density after surgical menopause Freya Schnabel*; Sarah Pivo; Esther Dubrovsky; Jennifer Chun; Shira Schwartz; Amber Guth; Deborah Axelrod Department of Surgery,
More informationMeasurements of Breast Density: No Ratio for a Ratio
2634 Measurements of Breast Density: No Ratio for a Ratio Gerco Haars, Paulus A.H. van Noord, Carla H. van Gils Diederick E. Grobbee, and Petra H.M. Peeters Julius Center for Health Sciences and Primary
More informationORIGINAL INVESTIGATION. New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk
ORIGINAL INVESTIGATION New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk Carolyn J. Crandall, MD, MS; Aaron K. Aragaki, MS; Rowan T. Chlebowski, MD,
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationDietary soy intake and changes of mammographic density in premenopausal Chinese women
Dietary soy intake and changes of mammographic density in premenopausal Chinese women 2010 WCRF International Conference, Nutrition, Physical Activity and Cancer Prevention: Current Challenges, New Horizons
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationGertraud Maskarinec, Ian Pagano, Galina Lurie, Lynne R. Wilkens, and Laurence N. Kolonel
American Journal of Epidemiology Copyright ª 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A. Vol. 162, No. 8 DOI: 10.1093/aje/kwi270 Advance Access publication
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer Meghan E. Work 1, Laura L. Reimers 1, Anne S. Quante 1,2,3,
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationbreast cancer; relative risk; risk factor; standard deviation; strength of association
American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationMammographic Density and the Risk and Detection of Breast Cancer
The new england journal of medicine original article Mammographic Density and the Risk and Detection of Breast Cancer Norman F. Boyd, M.D., D.Sc., Helen Guo, M.Sc., Lisa J. Martin, Ph.D., Limei Sun, M.Sc.,
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority:
1 ARIC STUDY MANUSCRIPT PROPOSAL # 714 PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1. a. Full Title: Effect of menopausal status on mood: The influence of demographic
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationBreast Density. Information for Health Professionals
Breast Density Information for Health Professionals BreastScreen NSW provides free screening mammography to asymptomatic women aged 50-74 every two years, with the aim of diagnosing breast cancer at an
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationReproductive and Hormonal Factors Associated with Fatty or Dense Breast Patterns among Korean Women
breast cancer risk is thought to be increased by 2 to 5-fold in women with dense breasts [3,4]. Although controversies remain in choosing the precise method of measuring breast density in comparisons between
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationThe relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen progestin
Human Reproduction Vol.20, No.6 pp. 1741 1745, 2005 Advance Access publication April 21, 2005 doi:10.1093/humrep/deh820 The relationship between mammographic density and duration of hormone therapy: effects
More informationInfluence of different HRT regimens on mammographic density
Maturitas 50 (2005) 105 110 Influence of different HRT regimens on mammographic density Hans Junkermann a,, Thomas von Holst b, Eva Lang c, Viatcheslav Rakov c a Ruprecht-Karls-Universität Heidelberg,
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationMammographic Density a Risk Factor for Breast Cancer
Prague Medical Report / Vol. 108 (2007) No. 3, p. 205 214 205) Mammographic Density a Risk Factor for Breast Cancer Fait T., Žižka Z. Department of Gynaecology and Obstetrics, Charles University in Prague,
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationEffects of a short-term suspension of hormone replacement therapy on mammographic density
FERTILITY AND STERILITY VOL. 76, NO. 3, SEPTEMBER 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of a short-term
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationSupplementary Table 4. Study characteristics and association between OC use and endometrial cancer incidence
Supplementary Table 4. characteristics and association between OC use and endometrial cancer incidence a Details OR b 95% CI Covariates Region Case-control Parslov, 2000 (1) Danish women aged 25 49 yr
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationReliability of Reported Age at Menopause
American Journal of Epidemiology Copyright 1997 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 146, No. 9 Printed in U.S.A Reliability of Reported Age at Menopause
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationPROSPECTIVE STUDIES HAVE
ORIGINAL CONTRIBUTION Serum Estradiol Level and Risk of Breast Cancer During Treatment With Steven R. Cummings, MD Tu Duong, MA Emily Kenyon, PhD Jane A. Cauley, DrPH Malcolm Whitehead, MB,BS, FRCOG Kathryn
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More informationMammographic density and breast cancer risk: a mediation analysis
Rice et al. Breast Cancer Research (2016) 18:94 DOI 10.1186/s13058-016-0750-0 RESEARCH ARTICLE Open Access Mammographic density and breast cancer risk: a mediation analysis Megan S. Rice 1*, Kimberly A.
More informationObservational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies
Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure
More informationA Comparative Study of Volumetric and Area-Based Breast Density Estimation in Digital Mammography: Results from a Screening Population
A Comparative Study of Volumetric and Area-Based Breast Density Estimation in Digital Mammography: Results from a Screening Population Despina Kontos, Predrag R. Bakic, Raymond J. Acciavatti, Emily F.
More informationNo effect of exercise on insulin-like growth factor (IGF)-1, insulin and glucose in young women participating in a 16-week randomized controlled trial
University of North Florida UNF Digital Commons Nutrition and Dietetics Faculty Publications Department of Nutrition and Dietetics 11-2010 No effect of exercise on insulin-like growth factor (IGF)-1, insulin
More informationSupplementary Online Content
Supplementary Online Content Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women s Health Initiative randomized
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationROKSANA KARIM, MBBS, PHD UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES, CA
Gonadotropin and Sex Steroid Levels in HIVinfected Premenopausal Women and Their Association with Subclinical Atherosclerosis in HIVinfected and -uninfected Women in the Women s Interagency HIV Study (WIHS)
More informationDiscussing breast cancer and hormone replacement therapy with women
INTERPRETING KEY TRIALS PELIN BATUR, MD Section of Women s Health, Department of General Internal Medicine, Gault Women s Health and Breast Pavilion, The Cleveland Clinic HOLLY L. THACKER, MD, FACP Departments
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationCOMPARED WITH PLACEBO,
IGINAL INVESTIGATION Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke Rozenn N. Lemaitre, PhD, MPH; Noel S. Weiss, MD, DrPH; Nicholas L. Smith,
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationRecreational physical activity and risk of triple negative breast cancer in the California Teachers Study
Ma et al. Breast Cancer Research (2016) 18:62 DOI 10.1186/s13058-016-0723-3 RESEARCH ARTICLE Open Access Recreational physical activity and risk of triple negative breast cancer in the California Teachers
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationHormone Treatments and the Risk of Breast Cancer
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationMethods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis
Methods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis Howard N. Hodis, MD, Wendy J. Mack, PhD, Donna Shoupe,
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationHow Neurosteroids Modulate Seizures in Children and Adults November 30, 2012
How Neurosteroids Modulate Seizures in Children and Adults November 30, 2012 Page B. Pennell, MD Brigham and Women s Hospital Harvard Medical School Boston, MA American Epilepsy Society Annual Meeting
More informationTamoxifen and Breast Density in Women at Increased Risk of Breast Cancer
Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer Jack Cuzick, Jane Warwick, Elizabeth Pinney, Ruth M. L. Warren, Stephen W. Duffy Background: Although mammographic breast density
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationActive, but not passive cigarette smoking was inversely associated with mammographic density
Cancer Causes Control (2010) 21:301 311 DOI 10.1007/s10552-009-9462-4 ORIGINAL PAPER Active, but not passive cigarette smoking was inversely associated with mammographic density Lesley M. Butler Ellen
More informationLong-term effects of tibolone on mammographic density. Key Words: Tibolone, mammographic density, long-term use
FERTILITY AND STERILITY VOL. 82, NO. 5, NOVEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. MENOPAUSE Long-term effects
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 332 JUNE 15, 1995 Number 24 THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN GRAHAM A. COLDITZ, M.B.,
More informationTHE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationDoes Body Mass Index Adequately Capture the Relation of Body Composition and Body Size to Health Outcomes?
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 147, No. 2 Printed in U.S.A A BRIEF ORIGINAL CONTRIBUTION Does
More informationSINCE ITS INCEPTION IN
CURRENT DRUG THERAPY DONALD G. VIDT, MD, AND ALAN BAKST, PHARMD, EDITORS The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: insights and highlights
More informationGeneral Biostatistics Concepts
General Biostatistics Concepts Dongmei Li Department of Public Health Sciences Office of Public Health Studies University of Hawai i at Mānoa Outline 1. What is Biostatistics? 2. Types of Measurements
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationTITLE: Breast Density Assessment by Dual Energy X-ray Absorptiometry in Women and Girls. Rachel Novotny, Ph.D. Honolulu, HI 96822
AD AWARD NUMBER: W81XWH-07-1-0489 TITLE: Breast Density Assessment by Dual Energy X-ray Absorptiometry in Women and Girls PRINCIPAL INVESTIGATOR: Gertraud Maskarinec, M.D., Ph.D. Rachel Novotny, Ph.D.
More informationRadiologist Assessment of Breast Density by BI-RADS Categories Versus Fully Automated Volumetric Assessment
Women s Imaging Original Research Gweon et al. Women s Imaging Original Research Hye Mi Gweon 1 Ji Hyun Youk Jeong-Ah Kim Eun Ju Son Gweon HM, Youk JH, Kim JA, Son EJ Keywords: automated evaluation, breast
More informationMammographic breast density may be the most undervalued
Article Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography Patricia A. Carney, PhD; Diana L. Miglioretti, PhD; Bonnie C.
More informationReproductive factors associated with mammographic density: a Korean co-twin control study
Breast Cancer Res Treat (2011) 128:567 572 DOI 10.1007/s10549-011-1469-3 BRIEF REPORT Reproductive factors associated with mammographic density: a Korean co-twin control study Joohon Sung Yun-Mi Song Jennifer
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationAmerican Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease
American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,
More informationComparison And Application Of Methods To Address Confounding By Indication In Non- Randomized Clinical Studies
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses 1911 - February 2014 Dissertations and Theses 2013 Comparison And Application Of Methods To Address Confounding By Indication
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationAssociation of Reproductive and Menstrual Characteristics with Mammographic Density
Original Articles Open Access Association of Reproductive and Menstrual Characteristics with Mammographic Density Sadaf Alipour * a,b, Ladan Hosseini c, Leila Bayani d, Azin Saberi a, Afsaneh Alikhassi
More information